Monoclonal Anti-Eotaxin-2 antibody produced in mouse

Accumulation of eosinophils is the hallmark of several medical conditions such as infections and systemic diseases. A number of chemokines stimulate the proliferation, migration and accumulation of eosinophils at the site of inflammation. Eotaxin-2 is chemoattractant that selectively acts on eosinophils and has minimal effect on other leukocytes. It is secreted in response to TNF-α, IL-5 or IL-3. The effect of Eotaxin is mediated by specific eotaxin receptor that induces activation of Gi proteins, MAPK signaling and involves changes in intracellular calcium levels and cytoskeletal reorganization. Eotaxin receptor is present on eosinophils, basophils and T-helper cells. Eotaxin coordinates the accumulation of these cells in response to allergic inflammation and homing of eosinophils to gastrointestinal tract and mucosal tissues
Monoclonal Anti-Eotaxin-2 (MPIF-2) recognizes recombinant human eotaxin-2, less than 0.03 % cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.

recombinant human eotaxin-2.

Anti-eotaxin-2 antibody may be used for neutralization assays at a working concentration of 1-5 μg/ml in the presence of 100 ng/ml of human recombinant eotaxin-2. The antibody is suitable for immunoblotting at 1-2 μg/ml concentration. For capture ELISA, a final concentration of 2 μg/ml may be used.

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline

Purified using protein G

The antibody neutralizes the biological activity of recombinant human eotaxin-2. It exhibits less than 0.03% cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.